- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07843225
Standard Closure vs. Integrated Mesh-Fascial Closure (IMFC) for Incisional Hernia Repair (IMFC)
Prospective Comparative Evaluation of the Integrated Mesh-Fascial Closure (IMFC) Technique Versus Standard Closure of the Abdominal Wall: A Quasi-Experimental, Non-Randomized Study
This study compares two surgical techniques for closing the abdominal wall in adult patients who have an incisional hernia (a weakness or opening in a previous surgical incision) or who require prophylactic mesh placement during a laparotomy.
In one group, the abdominal wall is closed using the standard technique, in which a polypropylene mesh is fixed independently from the fascial suture. In the other group, Integrated Mesh-Fascial Closure (IMFC) is used, a standardized execution of the technique of mesh incorporation into the fascial closure described by Jamal et al (Hernia, 2013).
The choice of technique is made by the patient after receiving information about both options and providing informed consent. Participants will be followed clinically and with imaging for 18 to 24 months to evaluate the safety, technical feasibility, and reproducibility of the IMFC technique, and to determine the incidence of hernia recurrence in both groups.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
Incisional hernia is one of the most frequent complications of abdominal surgery, with a reported incidence of 10-20% after laparotomy, and recurrence rates after mesh repair reaching 20-30% in long-term follow-up. In conventional techniques, primary fascial closure and mesh fixation are performed as two mechanically independent steps, concentrating tension on the suture line during the acute postoperative period.
The Integrated Mesh-Fascial Closure (IMFC) technique integrates a macroporous polypropylene mesh within a continuous fascial suture line (pattern: mesh → right fascial edge → left fascial edge → mesh), aiming to distribute tensile load simultaneously between the fascia and the prosthesis, potentially reducing the incidence of hernia recurrence compared to standard closure. The principle of incorporating the mesh into the fascial closure was described by Jamal et al in a retrospective series of 72 patients. IMFC standardizes its execution (suture material, 5-mm bites in mesh and fascia, anchoring of the suture line in healthy aponeurosis, and optional minimal peripheral fixation) and evaluates it prospectively against standard closure.
This is a prospective, comparative, quasi-experimental (non-randomized) study conducted at a single center (Hospital Zonal General de Agudos "Dr. Mario V. Larrain," Berisso, Argentina). Eligible patients choose, after informed consent, between standard mesh closure (Group A) or IMFC (Group B). Both groups follow the same clinical and imaging follow-up schedule (days 7, 15, 30; months 2, 6, 12, 18; and a final visit between 18 and 24 months).
The study is designed as an initial, hypothesis-generating comparison of safety, technical feasibility, and reproducibility across surgeons, intended to support a future randomized trial.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Facundo B Mattano, MD
- Puhelinnumero: +54 9 221 611-7976
- Sähköposti: mattanofacundo@outlook.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Emiliano D Gargiulo, MD
- Puhelinnumero: +54 2215371371
Opiskelupaikat
-
-
Buenos Aires
-
Berisso, Buenos Aires, Argentiina, 1923
- Rekrytointi
- Hospital Zonal General de Agudos "Dr. Mario V. Larrain
-
Ottaa yhteyttä:
- Facundo B Mattano, MD
- Puhelinnumero: +54 9 2216117976
- Sähköposti: mattanofacundo@outlook.com
-
Ottaa yhteyttä:
- Emiliano D Gargiulo, MD
- Puhelinnumero: +54 9 221 5371371
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Adults older than 18 years of age
- Patients with incisional (ventral) hernia
- Patients with recurrent incisional hernia
- Incisional hernias with a diameter greater than 4 cm
- Patients undergoing laparotomy with an indication for prophylactic mesh placement
Exclusion Criteria:
- Active surgical site infection
- Overt abdominal contamination
- Tissue necrosis or inability to achieve primary fascial closure
- Non-correctable loss of domain
- Pregnant women or women of childbearing potential planning pregnancy or not using contraception during the follow-up period
- Patients belonging to vulnerable populations, in accordance with Law 15.462 and applicable ethical guidelines
- Active oncologic disease (patients with a cured oncologic history may be included)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Standard Mesh Closure
Conventional fascial closure using a macroporous polypropylene mesh fixed independently from the closure suture |
Macroporous polypropylene mesh (FILAPROP™/MERIGROW™) plus non-absorbable polypropylene suture, placed using the conventional (independent) technique. |
|
Kokeellinen: Integrated Mesh-Fascial Closure - IMFC
Fascial closure using the Integrated Mesh-Fascial Closure (IMFC) technique: the mesh is incorporated within the trajectory of a single continuous fascial suture (pattern: mesh → right fascial edge → left fascial edge → mesh |
Same materials integrated into a single continuous suture line using the IMFC technique. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Recurrence rate of incisional hernia
Aikaikkuna: 18-24 months (final follow-up visit)
|
Proportion of participants with hernia recurrence, assessed by clinical physical examination and abdominal wall ultrasound, performed in all participants at 6 months and at the final visit (18-24 months). All ultrasound evaluations performed by the same sonographer throughout the study; the sonographer is aware of study participation but blinded to the specific surgical technique (IMFC vs. standard closure) received by each participant. |
18-24 months (final follow-up visit)
|
|
Rate of Major Intraoperative and Postoperative Complications
Aikaikkuna: Throughout study participation (up to 24 months)
|
Proportion of participants experiencing a serious adverse event (SAE), defined per ICH E6(R3) as death, a life-threatening event, hospitalization or prolongation of hospitalization, persistent or significant disability, or an unplanned surgical reintervention. Postoperative complications additionally graded using the Clavien-Dindo classification system (Grade I-V) to assess severity. |
Throughout study participation (up to 24 months)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Operative time and fascial closure time
Aikaikkuna: Intraoperative (during the surgical procedure)
|
Total operative time (from skin incision to skin closure) and fascial closure time (from start to completion of the mesh-fascial suture line), both measured in minutes and recorded intraoperatively by the surgical team using the operating room clock. |
Intraoperative (during the surgical procedure)
|
|
Postoperative Pain Assessed by the 0-10 Numeric Pain Rating Scale (NRS-11)
Aikaikkuna: Postoperative days 7, 15, and 30
|
Self-reported postoperative pain intensity measured using the 11-point Numeric Pain Rating Scale (NRS-11), an unabbreviated verbally- or visually-administered numeric scale ranging from 0 to 10, where 0 indicates "no pain" and 10 indicates "worst pain imaginable." Higher scores indicate worse (more severe) pain. Assessed at rest. |
Postoperative days 7, 15, and 30
|
|
Rate of Early Postoperative Complications (Infection, Seroma, Dehiscence, Hematoma)
Aikaikkuna: Up to 30 days postoperative
|
Proportion of participants with surgical site infection, seroma, wound dehiscence, or hematoma, identified by clinical examination at scheduled postoperative visits (days 7, 15, and 30) and graded according to the Clavien-Dindo classification. |
Up to 30 days postoperative
|
|
Total Direct Hospital Costs (ARS) Associated with Complications or Reoperations
Aikaikkuna: Up to 24 months (exploratory)
|
Total direct hospital costs, expressed in Argentine pesos (ARS), attributable to management of complications or unplanned reoperations, extracted from institutional administrative and billing records. Exploratory outcome; not powered for formal statistical comparison between groups. |
Up to 24 months (exploratory)
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Facundo B Mattano, MD, Hospital Zonal General de Agudos "Dr. Mario V. Larrain
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Postoperatiiviset komplikaatiot
- Patologiset prosessit
- Patologiset tilat, anatomiset
- Tyrä
- Tyrä, vatsa
- Patologiset tilat, merkit ja oireet
- Viiltotyrä
- Tyrä, Ventral
- Hormonit
- Hormonit, hormonikorvikkeet ja hormoniantagonistit
- Hypotalamuksen hormonit
- Peptidihormonit
- Neuropeptidit
- Peptidit
- Aminohapot, peptidit ja proteiinit
- Hermokudosproteiinit
- Proteiinit
- Aivolisäkkeen hormonit
- Aivolisäkkeen hormonit, etuosa
- Melanokortiinit
- Pro-Opiomelanokortiini
- Melanosyyttejä stimuloivat hormonit
Muut tutkimustunnusnumerot
- IMFC-HL-2026
- DISPO-2026-226-GDEBA-DIYCTMSAL (Muu tunniste: Comisión Conjunta de Investigaciones en Salud (CCIS))
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .